Insider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells 15,787 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 15,787 shares of the firm’s stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $9.87, for a total value of $155,817.69. Following the completion of the sale, the insider now directly owns 492,832 shares in the company, valued at $4,864,251.84. The trade was a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

David Moatazedi also recently made the following trade(s):

• On Thursday, March 27th, David Moatazedi sold 6,251 shares of Evolus stock. The stock was sold at an average price of $12.40, for a total value of $77,512.40.

Evolus Price Performance

EOLS opened at $9.70 on Friday. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The company has a market cap of $625.42 million, a price-to-earnings ratio of -10.66 and a beta of 1.11. The stock has a fifty day simple moving average of $11.32 and a two-hundred day simple moving average of $12.33. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on EOLS. BTIG Research began coverage on Evolus in a report on Thursday, April 17th. They set a “buy” rating and a $21.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Barclays lifted their target price on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $23.75.

Institutional Trading of Evolus

Hedge funds and other institutional investors have recently modified their holdings of the business. Tang Capital Management LLC lifted its position in Evolus by 3.1% during the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock valued at $55,171,000 after acquiring an additional 150,000 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Evolus by 2.0% during the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company’s stock valued at $38,906,000 after purchasing an additional 62,664 shares during the last quarter. Nantahala Capital Management LLC grew its stake in shares of Evolus by 10.8% in the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock worth $34,557,000 after buying an additional 305,300 shares during the last quarter. Caligan Partners LP boosted its holdings in Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after acquiring an additional 498,900 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Evolus by 1.7% during the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock valued at $16,746,000 after acquiring an additional 23,605 shares in the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.